An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder
Article first published online: 21 AUG 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 22, Issue 7, pages 455–462, October 2007
How to Cite
Centorrino, F., Meyers, A. L., Ahl, J., Cincotta, S. L., Zun, L., Gulliver, A. H., Kinon, B. J. and Houston, J. P. (2007), An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum. Psychopharmacol. Clin. Exp., 22: 455–462. doi: 10.1002/hup.870
- Issue published online: 25 SEP 2007
- Article first published online: 21 AUG 2007
- Manuscript Accepted: 10 JUL 2007
- Manuscript Received: 5 FEB 2007
- Eli Lilly and Company
- acute agitation;
- bipolar mania;
- schizoaffective disorder;
- IM olanzapine
To determine the effect of intramuscular (IM) olanzapine in severely agitated patients.
This was an open-label multicenter 1-week observational study of IM olanzapine treatment in severely agitated inpatients and psychiatric emergency services with bipolar mania (n = 22) or schizophrenia (n = 52). Mean change from baseline to 2 h post-first injection (LOCF) in agitation was assessed by PANSS-Excited Component (PANSS-EC) (score range: 5–35 points) mean change from baseline to 15, 30, 45, 60, 90, and 120 min post-first injection, and visit-wise mean changes from mixed-model repeated measures analysis of variance. Kaplan–Meier survival curve analyses estimated time to categorical response (rating of ≤3 points each PANSS-EC item).
Two hours post-injection of olanzapine (mean dose = 9.9 mg), patients exhibited mild calmness and agitation was significantly reduced by 19.2 ± 1.0 points (p < 0.001) (mean baseline = 29.0). Over 90% of the patients received only one injection in the first 24 h and 50% had a categorical response within 30 min.
Severely agitated patients responded rapidly after a single injection of olanzapine with mild levels of sedation and without serious treatment-emergent adverse events. Copyright © 2007 John Wiley & Sons, Ltd.